Evidence map›Paper›PMID 23765252›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2014

Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.

Melissa K McConechy, Jiarui Ding, Janine Senz, Winnie Yang, Nataliya Melnyk, Alicia A Tone, Leah M Prentice, Kimberly C Wiegand, Jessica N McAlpine, Sohrab P Shah and 4 more

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 289 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Endometriosis and Adenomyosis: From Pathogenesis to Follow-Up.Current issues in molecular biology · 2025
    Review
  19. Article
  20. Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Melissa K McConechyDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada.
Jiarui Ding1] Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada [2] Department of Computer Science, University of British Columbia, Vancouver, BC, Canada.
Janine SenzDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada.
Winnie YangDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada.
Nataliya MelnykDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada.
Alicia A ToneDivision of Gynecology Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Leah M PrenticeDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada.
Kimberly C WiegandDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada.
Jessica N McAlpineDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.
Sohrab P Shah1] Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada [2] Department of Computer Science, University of British Columbia, Vancouver, BC, Canada.
Cheng-Han LeeDepartment of Pathology and Laboratory Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
Paul J GoodfellowDepartment of Obstetrics and Gynecology, College of Medicine, Ohio State University, Columbus, OH, USA.
C Blake GilksDepartment of Pathology and Laboratory Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
David G Huntsman1] Department of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada [2] Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada.
BC Cancer Agency · CAUniversity of British Columbia · CAVancouver General Hospital · CAPrincess Margaret Cancer Centre · CAThe Ohio State University · US

Funding

DEFECTIVE DNA MISMATCH REPAIR IN ENDOMETRIAL CANCERSR01CA071754 · NCI · WASHINGTON UNIVERSITY · PI GOODFELLOW, PAUL JOSEPH · 1997 to 2009
$2.6M
Tissue and Pathology CoreP50CA134254 · NCI · WASHINGTON UNIVERSITY · PI POLLOCK, PAMELA M, POWELL, MATTHEW A · 2009 to 2011
$1.7M
NCI NIH HHS P50 CA134254NCI NIH HHS P50CA134254NCI NIH HHS R01 CA071754NCI NIH HHS R01CA71754
6 · The paper itself

Abstract

Ovarian endometrioid carcinomas and endometrial endometrioid carcinomas share many histological and molecular alterations. These similarities are likely due to a common endometrial epithelial precursor cell of origin, with most ovarian endometrioid carcinomas arising from endometriosis. To directly compare the mutation profiles of two morphologically similar tumor types, endometrial endometrioid carcinomas (n=307) and ovarian endometrioid carcinomas (n=33), we performed select exon capture sequencing on a panel of genes: ARID1A, PTEN, PIK3CA, KRAS, CTNNB1, PPP2R1A, TP53. We found that PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with low-grade ovarian endometrioid carcinomas (17%) (P<0.0001). By contrast, CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade endometrial endometrioid carcinomas (28%) (P<0.0057). This difference in CTNNB1 mutation frequency may be reflective of the distinct microenvironments; the epithelial cells lining an endometriotic cyst within the ovary are exposed to a highly oxidative environment that promotes tumorigenesis. Understanding the distinct mutation patterns found in the PI3K and Wnt pathways of ovarian and endometrial endometrioid carcinomas may provide future opportunities for stratifying patients for targeted therapeutics.

Indexed as

Mutationbeta CateninBiomarkers, TumorCarcinoma, EndometrioidDNA Mutational AnalysisEndometrial NeoplasmsExonsFemaleGenetic Predisposition to DiseaseHumansNeoplasm GradingOvarian NeoplasmsPhenotypePTEN PhosphohydrolaseTumor Microenvironmentbeta CateninBiomarkers, TumorCTNNB1 protein, humanPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID23765252
PMCPMC3915240
OpenAlexW1993925306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.